Morning Briefing
Summaries of health policy coverage from major news organizations
Viewpoints: GLP-1s Might Also Help Curve Cravings For Illegal Drugs; Weight Loss Drugs Cost Way Too Much
The New York Times: Ozempic's Next Magic Trick: Treating Drug Addiction
Could these medications — collectively known as GLP-1 receptor agonists — also fight America’s most difficult drug problems? (Maia Szalavitz, 10/18)
The Boston Globe: New Weight Loss Drugs Raise Questions Of Access, Costs
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs. (10/18)
The Atlantic: What Is This ‘Post-Birth Abortion’ Donald Trump Keeps Talking About?
In the post-Dobbs era, most states that had once used PPC as a tool to dissuade women from abortion don’t need to do so anymore; those states have banned abortion. Most states with abortion bans lack an exception for fetal anomalies, and when such an exception exists, it is only for a tiny subset of diagnoses. (Greer Donley and Jill Wieber Lens, 10/17)
